

Atty. Dkt. No. 041673-2069

In the Specification:

A marked up version showing the changes in the specification is attached. Please amend the specification as follows, to correct typographical errors:

Page 47, line 18, delete the sentence beginning "The fibroblasts", and replace it with the following:

F1 N.E. --The fibroblasts are then injected into the treatment site and cause the desired immune effect due to the presence of the accessory molecule ligand on the surface of those cells.--

Page 101, line 17, delete the sentence beginning "Total RNA", and replace it with the following:

F2 N.E. --Total RNA was isolated with the Qiagen RNeasy kit.--

Page 108, line 16, delete the sentence beginning "After the injection", and replace it with the following:

F3 N.E. --After the injection, the knee incision is closed with NEXABOND (Veterinary Products Laboratory).--

Page 110, line 33, through page 111, line 6 delete the sentence beginning "An *ex vivo* therapy", and replace it with the following:

F4 N.E. --An *ex vivo* therapy is similar to a protocol described for intra-articular transplantation of autologous synoviocytes retrovirally transduced to synthesize interleukin-1 receptor antagonist (Evan, Christopher et. al., Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis, Human Gene Therapy, Vol. 7, 1261-1280).--